← Back to all signals
RESEARCH PAPER ANALYSIS

Bayesian time-history modeling enhances Parkinsonian motor state classification for adaptive deep brain stimulation.

Using chronic at-home recordings from three PD patients, the authors demonstrate that Bayesian hidden Markov time-history models applied to cortical entrained-gamma (and STN beta) biomarkers improve hyperkinetic-state detection, prediction smoothness, and overall F1 accuracy versus instantaneous…

PMID42013882
JournalJournal of neural engineering
Publication Date2026-04-21
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

Using chronic at-home recordings from three PD patients, the authors demonstrate that Bayesian hidden Markov time-history models applied to cortical entrained-gamma (and STN beta) biomarkers improve hyperkinetic-state detection, prediction smoothness, and overall F1 accuracy versus instantaneous…

WHY IT MATTERS

Research significance

This work provides actionable, translational advances for adaptive deep brain stimulation—showing a practical modeling approach and choice of biomarker that can make real-time symptom-responsive neuromodulation more accurate and robust, accelerating device-level improvements even though it does not…

ABSTRACT

Source abstract

OBJECTIVE: Adaptive deep brain stimulation (aDBS) for Parkinson's disease is a recently-approved therapy that adjusts stimulation in response to neurophysiologic biomarkers of motor-symptom state. Most real-time implementations of aDBS rely on instantaneous, noise-susceptible classifiers that apply simple thresholds to neurophysiologic biomarkers. We examined whether incorporating temporal history through Bayesian state-space modeling improved motor-state classification compared to instantaneous discriminant classifiers. APPROACH: We analyzed naturalistic neural data from three patients with Parkinson's disease chronically implanted with investigational sensing-enabled DBS systems, recording from both the subthalamic nucleus (STN) and sensorimotor cortex. Biomarkers were extracted across multiple window lengths and labeled using wearable-derived bradykinesia and dyskinesia scores. Classifier behavior was evaluated using two biomarkers (cortical stimulation-entrained gamma and STN beta oscillations) across a factorial combination of two conditions: (1) instantaneous discriminant analysis vs. Bayesian time-history modeling via hidden Markov models (HMMs), and (2) single Gaussian vs. Gaussian mixture modeling of each motor state's biomarker distribution. Performance metrics included F1 scores, accuracy, prediction smoothness, latency, and computational load. MAIN RESULTS: Using entrained-gamma biomarkers, incorporating time history via HMMs significantly improved hyperkinetic-state detection (F1: +12.9 ± 1.8%; accuracy: +30.0 ± 2.7%; both padj < 0.001) with modest decreases in hypokinetic-state performance, yielding a net increase in average F1 (+4.7 ± 0.9%, p < 0.001). HMMs also yielded smoother and more accurate predictions for a given latency compared to simply increasing the window length used to extract neurophysiologic biomarkers. Entrained-gamma biomarkers outperformed STN beta biomarkers across all classifiers (average F1: +12.9% ± 0.5%, p < 0.001). All methods operated within sub-millisecond prediction times and demonstrated sublinear empirical computational scaling. SIGNIFICANCE: Bayesian time-history modeling enhanced motor-state classification while preserving the low latency and computational efficiency required for real-time aDBS. These findings, derived from chronic at-home recordings, support the translational potential of Bayesian state-space models for next-generation aDBS systems.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic